Infliximab infusion time in patients with inflammatory bowel diseases: Is longer really safer?

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 2, 2013, Pages 189-192

  Belhassan, Mehdi ^a   Zeitoun, Jean David ^a,b   Lefevre, Jérémie H ^c,d   Charachon, Antoine ^a   Amiot, Aurélien ^a,b   Le Baleur, Yann ^a,b   Sobhani, Iradj ^a,b   Delchier, Jean Charles ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; HYDROCORTISONE; INFLIXIMAB;

ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENTERITIS; FEMALE; HOT FLUSH; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRALGIA; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; EXANTHEMA; FEMALE; HOT FLASHES; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; MALE; MYALGIA; NAUSEA; RETROSPECTIVE STUDIES;

EID: 84876744168     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.07.004     Document Type: Article

References (13)

1. Buch M.H., Bryer D., Lindsay S., et al. Shortening infusion times for infliximab administration. Rheumatology 2006, 45:485-486.
2. Shergy W.J., Isern R.A., Cooley D.A., et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002, 29:667-677.
3. Van Vollenhoven R.F., Gullstrom E., Klareskog L. Feasibility of 1hour infliximab infusions. Ann Rheum Dis 2005, 64:654.
4. Yeckes A.R., Hoffenberg E.J. Rapid infliximab infusions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009, 49(1):151-154.
5. Rojany M, Wegelin J, Trudeau W et al. A rapid one-hour infusion of infliximab is well tolerated. Digestive disease week 2006, May 20-25, 2006, Los Angeles.
6. Bhat S., Sharma D., Doherty P., et al. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?. Inflamm Bowel Dis 2010, 16:1922-1925.
7. Breynaert C., Ferrante M., Fidder H., et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 2011, 106:778-785.
8. Salzberg BA, Kendall, K. Successful 1 hour infusions of infliximab for Crohn's disease patients in an outpatient office setting. Digestive disease week 2004. New Orleans, LA. Abstract 100033.
9. Lee T.W., Singh R., Fedorak R.N. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther 2011, 34(2):181-187.
10. Clare D.F., Alexander F.C., Mike S., et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009, 21(1):71-75.
11. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
12. Mantzaris G.J., Viazis N., Petraki K., et al. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. Eur J Gastroenterol Hepatol 2009, 21(9):1042-1048.
13. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.